Moderna: Now That The COVID Party Is Over, What’s Next? (NASDAQ:MRNA)

Thoughtful woman with hand on chin looking up


The COVID-19 Investment Thesis May Already Be Over

We previously covered Moderna (NASDAQ:MRNA) in December 2022, discussing its mixed prospects as the demand for its COVID offerings decelerated from the hyper-pandemic peak.

While the biotech company might report

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *